logo-loader
viewHumanigen, Inc.

Humanigen moves a step closer to a Phase III trial to tackle leading cause of death in coronavirus

As reported last week, lenzilumab is aimed at treating so-called cytokine storm, which can lead to acute respiratory distress syndrome (ARDS) associated with the current pandemic

Humanigen, Inc. -
Patients with the severe form of the disease experience viral pneumonia that can progress to ARDS and death

Humanigen Inc (OTCMKTS:HGEN) has moved a step closer in its plans to start a Phase III clinical trial for its lenzilumab antibidy to help coronavirus patients, namely submitting an initial protocol synopsis to the US Food and Drug Administration (FDA).

As reported last week, the biotech's monoclonal antibody lenzilumab is aimed at treating so-called cytokine storm, which can lead to acute respiratory distress syndrome (ARDS) associated with the current pandemic.

Humanigen planning Phase III clinical trial for lenzilumab to treat coronavirus patients; shares soar

There are now over 542,000 confirmed cases of coronavirus (COVID-19) globally and over 24,000 deaths.

Patients with the severe form of the disease experience viral pneumonia that can progress to ARDS and death.

A rapid escalation in ARDS presents a major challenge for health systems around the world given limited hospital beds and ventilators.

"Humanigen has pioneered the field of GM-CSF neutralization and, unlike others, has already conducted two Phase I and two Phase II studies, including in patients with severe respiratory conditions, with excellent safety results," said Dr Cameron Durrant, chief executive of Humanigen.

"We have been working on prevention of cytokine storm for nearly three years. Lenzilumab has an excellent safety and tolerability profile and has not been associated with serious adverse events, including in patients who are immunosuppressed or with severe asthma.

"Subject to discussion and agreement with regulatory authorities, we intend to progress as quickly as possible with this study," the company boss added.

Humanigen's clinical study, if approved, will be a muti-centre, US, randomized, controlled, clinical trial with lenzilumab.

Shares in New York ticked up 4.6% to $1.35 each.

---Updates for share price---

Contact the author at [email protected]

Quick facts: Humanigen, Inc.

Price: 0.94 USD

OTCMKTS:HGEN
Market: OTCQB
Market Cap: $118.76 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Humanigen, Inc. named herein, including the promotion by the Company of Humanigen, Inc. in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Humanigen achieves significant milestone in dosing first coronavirus patient...

Humanigen Inc (OTCQB:HGEN) CEO Cameron Durrant tells Proactive its first coronavirus patient has been dosed in a Phase 3 trial of its drug lenzilumab. Durrant says the now ongoing trial is the first randomized, double-blind, placebo-controlled, multi-center, Phase 3 study of an anti-GM-CSF...

2 weeks ago

2 min read